AEZS~ huge success in Prostate Cancer trial! A phase I trial in prostate cancer indicated that nine out ten evaluable patients achieved disease stabilization through administration of zoptarelin doxorubicin.
AEZS cancer drug founder got Nobel Prize in Medicine
1) Zoptarelin doxorubicin was developed by Andrew V. Schally while at the Tulane University School of Medicine, New Orleans and subsequently at the Sylvester Comprehensive Cancer Center, University of Miami.
The U.S. Food and Drug Administration (FDA) has granted it orphan drug status for ovarian cancer and endometrial cancer.
A phase I trial in prostate cancer indicated thatnine out ten evaluable patients achieved disease stabilization through administration of zoptarelin doxorubicin.
News 
Market Data 
Discover 
